Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC increased its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 6.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 725,621 shares of the company’s stock after acquiring an additional 46,041 shares during the period. Geode Capital Management LLC owned about 1.79% of Keros Therapeutics worth $42,146,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of KROS. KBC Group NV increased its stake in Keros Therapeutics by 52.0% during the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after purchasing an additional 432 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after purchasing an additional 280 shares in the last quarter. Values First Advisors Inc. purchased a new stake in Keros Therapeutics during the 3rd quarter worth approximately $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Keros Therapeutics during the 2nd quarter worth approximately $128,000. Finally, LMR Partners LLP purchased a new position in Keros Therapeutics in the 3rd quarter valued at approximately $213,000. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Price Performance

Shares of KROS opened at $17.12 on Tuesday. Keros Therapeutics, Inc. has a 1-year low of $15.67 and a 1-year high of $73.00. The stock has a market cap of $693.48 million, a PE ratio of -3.29 and a beta of 1.20. The firm has a fifty day moving average price of $54.97 and a 200 day moving average price of $51.62.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The firm had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business’s revenue was up 4750.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.33) earnings per share. As a group, equities analysts expect that Keros Therapeutics, Inc. will post -5.26 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Truist Financial reduced their price objective on Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating on the stock in a research note on Monday. HC Wainwright decreased their price objective on Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Oppenheimer lowered their price objective on Keros Therapeutics from $102.00 to $63.00 and set an “outperform” rating for the company in a research report on Monday, December 16th. Scotiabank reduced their target price on shares of Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating on the stock in a report on Friday, December 13th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Keros Therapeutics in a report on Friday, November 22nd. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, Keros Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $75.00.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.